Skip to main content
. 2015 Aug 5;16(8):18033–18053. doi: 10.3390/ijms160818033

Table 7.

Treatment recommendations for HCV recurrence after liver transplantation.

HCV Genotype Therapy
GT 1
  • ●

    Ledipasvir + Sofosbuvir + Ribavirin for 12 weeks. In case of Ribavirin intolerance treatment prolongation up to 24 weeks should be evaluated.

  • ●

    Simeprevir + Sofosbuvir ± Ribavirin for 12 weeks.

  • ●

    Paritaprevir, ritonavir, Ombitasvir and Dasabuvir with Ribavirin for 12 weeks (genotype 1b) or 24 weeks (genotype 1a with cirrhosis).
GT 2
  • ●

    Sofosbuvir + Ribavirin for 12 weeks (also accounts for patients with post-transplant compensated cirrhosis). In decompensated cirrhosis prolongation up to 24 weeks should be evaluated.
GT 3
  • ●

    Sofosbuvir + Daclatasvir + Ribavirin for 12–24 weeks depending on presence of post-transplant cirrhosis.
GT 4
  • ●

    Ledipasvir + Sofosbuvir + Ribavirin for 24 weeks.

  • ●

    Paritaprevir, ritonavir and Ombitasvir plus Ribavirin for 12 or 24 weeks depending on presence of post-transplant cirrhosis.

  • ●

    Sofosbuvir + Simeprevir ± RBV for 12 weeks.
GT 5/6
  • ●

    No data available.

Recommendations for patients with HCV recurrence after liver transplantation. Since drug approval of the DAAs vary, health care cost recovery should be evaluated prior to treatment start. Recommendations are given for DAA combinations with most data available at the moment.